Press Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard Nov 14, 2024 Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 Nov 6, 2024 Evofem Secures Investor Support for Proposed Merger through Voting Agreements Oct 28, 2024 Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem Sep 20, 2024 Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025 Sep 9, 2024 Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024 Aug 20, 2024 Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution Aug 14, 2024 Evofem Biosciences Announces Financial Results for the Second Quarter of 2024 Jul 25, 2024 Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st Jul 23, 2024 Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1 Jul 15, 2024 Lupin Divests U.S. Commercial Women's Health Specialty Business - SOLOSEC - to Evofem Biosciences Show 5102550100 per page«123456789…24»
